Navigation Links
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Date:11/30/2009

to ten per million, or approximately 2,000 to 5,000 patients in the E.U. and 1,200 to 3,100 patients in the U.S. Approximately 50 percent of LEMS patients diagnosed have small cell lung cancer.

Patients with LEMS typically present with fatigue, muscle pain and stiffness. The weakness is generally more marked in the proximal muscles particularly of the legs and trunk. Other problems include reduced reflexes, drooping of the eyelids, facial weakness and problems with swallowing. Patients often report a dry mouth, impotence, constipation and feelings of light headedness on standing. On occasion these problems can be life threatening when the weakness involves respiratory muscles. A diagnosis of LEMS is generally made on the basis of clinical symptoms, electromyographic testing and the presence of autoantibodies against voltage gated calcium channels.

Current treatment of LEMS can consist of strategies directed at the underlying malignancy if one is present. Unfortunately, therapy of small cell lung cancer is limited and outcomes are generally poor. Immunosuppressive agents have been tried but success is limited by toxicity, and difficulty administering the regimens. A mainstay of therapy has been 3,4-DAP but its use in practice has been limited by the drug's availability. This problem will be addressed by the introduction of BioMarin's product.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan®
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 Express Diagnostics ... tests, today announced that it has received Class III ... and sell its DrugCheck® NxStep Onsite Drug Screen ... of the rapid screening device in near-patient settings, such ... Screen Cup received Health Canada Class III approval for ...
(Date:6/18/2013)... Santa Clara, CA (PRWEB) June 18, 2013 ... compared to standard size SEMs but have limited performance ... and lower resolution. Full size SEMs would normally provide ... require more knowledge to operate and have a higher ... SEMs address the gap between these two types ...
(Date:6/18/2013)... 2013 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its preliminary unaudited financial results for the fourth quarter ... 31, 2013. Fourth Quarter of Fiscal ... of fiscal 2013 increased by 33.3% to RMB133.0 million ...
(Date:6/18/2013)... Angeles, CA (PRWEB) June 18, 2013 (PRWEB) June ... construction’s #1 time and attendance system in North ... software that shares employee data and payroll records ... AccountLinx Plus automates ExakTime software setup ... The software imports employee data from a business’ ...
Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13ExakTime Introduces AccountLinx Plus 2
... , , , ... , With the introduction of the Pwo Master, Roche Applied,Science ... up to,3 kb, providing the highest possible fidelity during PCR,synthesis. , ... , Pwo Master is a premixed double-concentrated formulation,that contains PwoSUPER ...
... , , , ... , , , , ... these reagents significantly influences the results of your experiments. , ... , Roche Applied Science developed a new manufacturing ...
... , , , ... , Now that we know complete,genomes, ... by a,genome at a specific stage.,Assembling the protein puzzle,presents an even ... is the complexity of protein,structure and function, and the sensitivity of ...
Cached Biology Technology:Pwo Master*:,Simplify Setup of Your Proofreading PCRs 2Pwo Master*:,Simplify Setup of Your Proofreading PCRs 3Tools for Proteomic Science II 2Tools for Proteomic Science II 3Tools for Proteomic Science II 4
(Date:6/19/2013)... is the most potent physiological anabolic agent for ... synthesis of lipids, protein and carbohydrates, and inhibiting ... It also plays a major role in stimulating ... is metabolized and removed from the blood following ... molecular mechanisms by which insulin regulates glucose uptake ...
(Date:6/19/2013)... form into the most perfectly spherical large objects in ... in a new study. It appears in ACS, journal ... Langmuir. , Julyan Cartwright, Antonio G. Checa and Marthe ... prized pearls have perhaps the most perfectly spherical, or ... are visible without a microscope. Pearls develop as nacre ...
(Date:6/19/2013)... ITHACA, N.Y. A Cornell University study offers further ... 4 million to 6 million years ago was profoundly ... in turning genes on and off. , The study, ... evidence for a 40-year-old hypothesis that regulation of genes ... is little difference between humans and chimps in the ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
... Penn State University have discovered that adding a dash of ... spongy, reusable blocks that have an astounding ability to absorb ... of potential innovations for the material created in a single ... puts kinks and elbows into the nanotubes as they grow ...
... to treating one of the most common types of ... called FLT3, according to new research led by physician-scientists ... Diller Family Comprehensive Cancer Center. Published this week ... certain activating mutations in the FLT3 gene as targets ...
... of researchers led by Boston University School of Medicine ... associated with decreasing the volume of the hippocampus. The ... an important role in the formation of specific, new ... disease lose. The findings may have broad implications in ...
Cached Biology News:Nanosponges soak up oil again and again 2Nanosponges soak up oil again and again 3An Achilles heel of AML 2An Achilles heel of AML 3BUSM researchers identify genes that influence hippocampal volume 2
Human Cystatin A MAb (Clone 224705)...
... Molecular Probes is pleased to ... for the ultrasensitive detection of primary ... at Indiana University, the ATTO-TAG reagents ... o-phthaldialdehyde (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, ...
...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Biology Products: